Treatment of headaches with botulinum toxin

Expert Review of Neurotherapeutics

Volumn 6, Issue 3, 2006, Pages 313-322

  Samton, Julia ^a   Mauskop, Alexander ^b  

^a New York Headache Center   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Botulinum toxin; Chronic daily headache; Headache; Headache management; Migraine; Tension type headache

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CANDESARTAN; LIDOCAINE; NONSTEROID ANTIINFLAMMATORY AGENT; ORPHAN DRUG; PLACEBO; PROPRANOLOL; SODIUM CHLORIDE; TIMOLOL; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; VALPROATE SEMISODIUM; VENLAFAXINE;

ALLERGIC REACTION; ALOPECIA; AUTONOMIC DYSFUNCTION; BODY WEIGHT DISORDER; BRADYCARDIA; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; EYE ASYMMETRY; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HEADACHE AND FACIAL PAIN; HUMAN; INJECTION PAIN; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; LIBIDO DISORDER; MIGRAINE; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYALGIA; NECK PAIN; PARALYSIS; PARESTHESIA; PATIENT COMPLIANCE; PHYSICIAN; PTOSIS; QUALITY OF LIFE; RASH; REVIEW; SALIVATION DISORDER; SEDATION; SIDE EFFECT; SYNCOPE; TACHYPHYLAXIS; THORAX PAIN; VOMITING; WEAKNESS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

BOTULINUM TOXINS; HEADACHE; HUMANS;

EID: 33645866484     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.6.3.313     Document Type: Review

References (56)

1. Johnson RT, Griffin JW, McArthur JC. Current therapy in Neurologic Disease. Mosby, MO, USA (2002).
2. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 22, 491-512 (2002).
3. Sandor PS. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64, 713-715 (2005).
4. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-Based Guidelines For Migraine Headache In The Primary Care Setting: Pharmacological Management For Prevention of Migraine. American Academy of Neurology, MN, USA (2000).
5. Binder WJ, Brin MF, Blitzer A et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol. Head Neck Surg. 123, 669-676 (2000).
6. Giladi N. The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J. Neurol. Sci. 152, 132-135 (1997).
7. Guyron B, Tucker T, Davis J. Surgical treatment of migraine headaches. Plastic Reconstr. Surg. 109, 2183-2189 (2002).
8. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 38, 468-471 (1998).
9. Guyron B, Varghi A, Michelow BJ, Thomas T, Davis J. Corrugator supercilii muscle resection and migraine headaches. Plastic Reconstr. Surg. 106, 429-434 (2000).
10. Smuts JA, Schultz D, Barnard A. Mechanism of action of botulinum toxin type A in migraine prevention: a pilot study. Headache 44, 801-805 (2004).
11. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(Suppl. 1), S9-S15 (2003).
12. Caputi AC, Firetto V. Therapuetic blockade of greater occipital and supraorbital nerves in migraine patients. Headache 37, 174-179 (1997).
13. Durham PL, Cady R, Cady R. Regulation of calcitonin gene related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implication for migraine therapy. Headache 44, 35-43 (2004).
14. Carruthers A. Botulinum toxin type A. J. Am. Acad. Dermatol. 2, 284-290 (2005).
15. Markey AC. Dysport. Dermatol. Clin. 22, 213-219 (2004).
16. Cornelia CL, Jankovic J, Shannon KM et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Dystonia study group. Neurology 65, 1423-1429 (2005).
17. Titner R, Gross R, Winzer UF et al. Autonomic function after botulinum toxin type A or B: a double blind, randomized trial. Neurology 65, 765-767 (2005).
18. Borodic GE, Joseph M, Fay L et al. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12, 392-399 (1990).
19. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov. Disord. 9, 31-39 (1994).
20. Borodic GE, Pearce LB, Smith KL et al. Botulinum B toxin as an alternative to botulinum A toxin: a histologic study. Ophthal. Plast. Reconstr. Surg. 9, 182-190 (1993).
21. Shaari CM, Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 16, 964-969 (1993).
22. Flynn TC, Clark RE II. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol. Surg. 29, 519-522 (2003).
23. Arezzo JC, Litwak MS, Caputo FA et al. Paralytic effects of BoNT-A VS BoNT-B in injected and non-injected muscles: implications to toxin therapy. Pain Med. 2, 239 (2001).
24. Cote TR. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J. Am. Acad Dermatol. 53, 407-415 (2005).
25. Silberstein S, Mathew N, Saper J et al. Botulinum toxin type A as a migraine preventive treatment. Headache 40, 445-450 (2000).
26. Evers S, Vollmer-Haase J, Schwaag S. Botulinum toxin A in the prophylactic treatment of migraine - a randomized double blind, placebo controlled study. Cephalalgia 24, 838-843 (2004).
27. Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A BOTOX® in the preventative treatment of migraine. Presented at the American Headache Society 44th Annual Scientific Meeting. WA, USA, June 21-23, abstract S106 (2002).
28. Brin, MF, Swope DM, Obrian C, Abassi S, Pogoda JM. Botox for migraine: double blinded, placebo controlled, region specific evaluation. Cephalalgia 20, 421-422 (2000).
29. Relja MA. Botulinum toxin type-A reduces acute medication (triptans) use in migraine patients [abstract]. Neurology 60, 147 (2003)
30. Conway S, Delplanche C, Crowder J et al. Botox therapy for refractory chronic migraine. Headache 45(4), 355-357 (2005).
31. Eross DO, Gladstone JP, Lewisa SL et al. Duration of migraine is a predictor for response to botulinum toxin type A. Headache 45(4), 308-312 (2005).
32. Blumenfeld A. Botulinum toxin type A as an effective preventive treatment in headache [abstract]. Headache 43, 576 (2003).
33. Mathew N, Kaup A, Kailasam J. Botulinum toxin type A modifies chronic migraine; further long-term (3 years) experience with up to ten sets of treatments [abstract]. Headache 43, 576 (2003).
34. Krusz J. Intradermal botulinum toxin, type A, for cervicogenic migraine [abstract]. Headache 42, 405 (2002).
35. Pollman W, Keidel M, Pfaffenrath V. Headache and the cervical spine: a critical review. Cephalalgia 17, 801-816 (1997).
36. Mauskop A. Long term use of botulinum toxin type A in the treatment of episodic and chronic migraine headaches [abstract]. Headache 42, 454-455 (2002).
37. Mathew NT, Frishberg BM, Gawel M. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double blind controlled trial. Headache 4, 293-303 (2005).
38. Dodick DW, Mauskop AM, Elkind AH et al. Botulinum toxin type A for nthe prophylaxis of chronic daily headache: a subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind placebo controlled study. Headache 45, 308-314 (2005).
39. Klapper JA, Mathew NT, Klapper A, Kailasam J. Botulinum toxin type A (BT-A) for the prophylaxis of chronic daily headache. Cephalalgia 20(4), 292-293 (2002).
40. Tepper SJ, Bigal ME, Sheftell FD et al. Botulinum neurotoxin type A in the preventative treatment of refractory headache: a review of 100 consecutive cases. Headache 44, 794-800 (2004).
41. Edwards KR. Botulinum toxin type A (Botox) for chronic daily headaches [abstract]. Headache 42, 429 (2002).
42. Smuts JA, Baker MK, Smuts HM et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur. J. Neurol. 6, S99-S102 (1999).
43. Relja MA. Treatment of tension type headache by injection of botulinum toxin type A: double blind placebo controlled study. Eur. J. Neurol. 4, S71-S73 (1997).
44. Sebastian FT, de Bruijn M. Treatment of chronic tension type headache with botulinum toxin; a double blind, placebo controlled clinical trial [abstract]. Neurology 60, 148 (2003).
45. Schulte Mattler WJ, Krack P, BoNTTH Study Group. Treatment of chronic tension type headache with botulinum toxin A: a randomized, double blind, placebo controlled multicenter study. Pain 109, 110-114 (2004).
46. Rollnick JD, Tanneberger O, Scgubert M et al. Treatment of tension type headache with botulinum toxin type A: a double blind placebo controlled study. Headache 40, 300-305 (2000).
47. Padberg M, De Bruijn SJ. Treatment of chronic tension type headache with botulinum toxin: a double blind placebo controlled trial [abstract]. Neurol. 63(Suppl.) (2002).
48. Ondo WG, Vuong KD, Derman H. Botulinum toxin A for chronic daily headache: a randomized, placebo controlled, parallel design study. Cephalalgia 1, 60-65 (2004).
49. McAllister P. Patient-reported improvements in headache and change in headache medication usage in a cohort treated with botulinum toxin type-A (Botox) [abstract]. Headache 43, 577 (2003).
50. Miller T, Denny L. Botulinum toxin A (Allergan) for chronic intractable headache: equally effective with or without concomitant neck pain [abstract]. Headache 43, 579 (2003).
51. Troost T, Rosenberg JR, Wiles R. Improvement in intractable headache with repeated botulinum toxin type A treatment [abstract]. Neurology 60(5 Suppl. 1), A323-A324 (2003).
52. Blumenfeld AM. Impact of botulinum toxin type A treatment on medication costs and usage in difficult-to-treat chronic headache: case studies. Headache Quar. 12, 241-244 (2001).
53. Troost BT. Botulinum toxin type A (BOTOX) therapy for intractable headache [abstract]. Headache 42, 435-436 (2002).
54. Smuts JA, Baker MK, Smuts HM et al. Prophylactic treatment of chronic tension type headache using botulinum toxin type A. Eur. J. Neurol. 6, S99-S102 (1999).
55. Miller T, Denny L. Botulinum toxin A (Allergan) for chronic intractable headache: equally effective with or without concomitant neck pain [abstract]. Headache 43, 577 (2003).
56. Freund BJ, Schwartz M. Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J. Rheumatol. 27, 481-484 (2000).